F. no. 12(24)/2021/DP/NPPA/Div.II (Vol.II)-Part(1)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceuticals Pricing Authority

5th / 3rd floor, YMCA Cultural Centre Building,
1, Jai Singh Road, New Delhi – 110 001
Dated: 13.09.2025

OFFICE MEMORANDUM

Subject: Implementation of revision in maximum retail price (MRP) due to reduction in Goods and Service Tax (GST) rates

Please refer to OM of even number, dated 12.09.2025, conveying directions regarding the above subject.

2. In this regard, the undersigned is directed to convey the following revisions:

Direction in paragraph 2 of OM dated 12.09.2025	Revised direction
iii. The manufacturer/marketing companies shall issue revised price list or supplementary price list, in Form V/VI to the dealers, retailers, State Drug Controllers and the Government reflecting the revised GST rates and Revised MRP.	iii. The manufacturer/marketing companies shall issue revised price list or supplementary price list, in Form V/VI, to the dealers and retailers for display to consumers, and to State Drug Controllers and the Government, reflecting the revised GST rates and Revised MRP.
vi. However, the manufacturer/marketing companies who desire to re-label or re-sticker the stock available in the market, may do so in a phased manner so that it does not cause shortage of drugs/formulations (including medical devices) in the market. In this regard CDSCO has already issued necessary directions on 11.09.2025 under Rule 104A of the Drugs and Cosmetics Rules, 1945 (copies enclosed).	vi. However, while adhering to the directions at i. to iv. above, the manufacturer/marketing companies who desire to re-label or re-sticker the stock available in the market, may do so in a phased manner so that it does not cause shortage of drugs/formulations (including medical devices) in the market. In this regard CDSCO has already issued necessary directions on 11.09.2025 (copies enclosed).

13/09/2025
(Sanjay Kumar)
Advisor (Cost)

To,
All the manufacturers, marketers and associations of drugs/formulations, for compliance

Copy to:
1. PSO to Secretary (Pharma), Government of India
2. Drugs Controller General (India)
3. All the Drugs Controllers / Food & Drug Administrations of all the State / UT Governments